论文部分内容阅读
目的设计合成肿瘤抗原MAGE-12的B细胞表位并研究其表位联合应用的免疫原性。方法在MAGE-12的B细胞表位序列MAGE-123-14(LEQRSQHCKPEE)、MAGE-1282-93(QSDEGSSNEEQE)的基础上,采用4分枝多重抗原肽结构设计合成抗原肽后分MAGE-123-14组、MAGE-1282-93组、MAGE-123-14联合MAGE-1282-93组,分别以MAGE-123-14、MAGE-1282-93、MAGE-123-14联合MAGE-1282-93抗原肽免疫C-57BL/6小鼠,产生多克隆抗体,应用ELISA和免疫组化实验检测多克隆抗体是否为抗原肽的特异性抗体。结果免疫C-57BL/6小鼠后可产生MAGE-12的抗原特异性的多克隆抗体,且多表位抗原肽联合使用组抗体效价高于单表位抗原肽组产生的抗体效价。结论证明MAGE-12的B细胞多表位抗原肽联合使用的免疫原性强于单个B细胞表位抗原肽的免疫原性。
OBJECTIVE: To design B cell epitopes for the synthesis of tumor antigen MAGE-12 and to study the immunogenicity of its combination with epitopes. Methods Based on the sequence of MAGE-123 (MAGE-123-14 (LEQRSQHCKPEE) and MAGE-1282-93 (QSDEGSSNEEQE), the MAGE-12 peptide was designed and synthesized. MAGE-1282-93 group, MAGE-123-14 combined with MAGE-1282-93 group, MAGE-123-14, MAGE-1282-93 and MAGE- The C-57BL / 6 mice were immunized to produce polyclonal antibodies. ELISA and immunohistochemistry were used to detect whether polyclonal antibodies were specific for antigenic peptides. Results The results of immunization of C-57BL / 6 mice with MAGE-12 antigen-specific polyclonal antibodies, and multi-epitope antigen peptide combination group titers higher than the single-epitope antigen peptide antibody titers. The conclusion demonstrates that the immunogenicity of the combination of MAGE-12 B-cell multi-epitope antigenic peptides is stronger than the immunogenicity of a single B cell epitope antigenic peptide.